

1     **Aorta-on-a-chip reveals impaired mitochondrial dynamics as a**  
2     **therapeutic target for aortic aneurysm in bicuspid aortic valve**  
3     **disease**

4     Mieradilijiang Abudupataer<sup>1</sup>, Shichao Zhu<sup>1</sup>, Shiqiang Yan<sup>2</sup>, Kehua Xu<sup>2</sup>, Jingjing Zhang<sup>2</sup>, Shaman  
5     Luo<sup>2,3</sup>, Wenrui Ma<sup>1</sup>, Md. Fazle Alam<sup>2,3</sup>, Yuyi Tang<sup>2</sup>, Hui Huang<sup>2</sup>, Nan Chen<sup>1</sup>, Li Wang<sup>2</sup>, Guoquan  
6     Yan<sup>2</sup>, Jun Li<sup>1</sup>, Hao Lai<sup>1</sup>, Chunsheng Wang<sup>1\*</sup>, Kai Zhu<sup>1\*</sup>, Weijia Zhang<sup>1,2,3\*</sup>

7     <sup>1</sup> Department of Cardiac Surgery and Shanghai Institute of Cardiovascular Diseases, Zhongshan  
8     Hospital, Fudan University, Shanghai 200032, China; <sup>2</sup> Institutes of Biomedical Sciences,  
9     Shanghai Medical College, Fudan University, Shanghai 200032, China; <sup>3</sup> The State Key  
10    Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 200438, China.

11    # To whom correspondence should be addressed: Kai Zhu, Chunsheng Wang & Weijia Zhang

12    **Emails:**                    zhu.kai1@zs-hospital.sh.cn;                    wangchunsheng@fudan.edu.cn;  
13    weijiazhang@fudan.edu.cn

14    **Keywords:** organ-on-a-chip, thoracic aortic aneurysm, bicuspid aortic valve, mitochondrial  
15    dynamics, human aortic smooth muscle cells

16 **Abstract**

17 **Background:** Bicuspid aortic valve (BAV) is the most common congenital cardiovascular disease  
18 in general population and is frequently associated with the development of thoracic aortic  
19 aneurysm (TAA). There is no effective strategy to intervene with TAA progression due to an  
20 incomplete understanding of the pathogenesis. Insufficiency of NOTCH1 expression is highly  
21 related to BAV-TAA, but the underlying mechanism remains to be clarified.

22 **Methods:** A comparative proteomics analysis was used to explore the biological differences  
23 between non-diseased and BAV-TAA aortic tissues. A microfluidics-based aorta-on-a-chip model  
24 was constructed to evaluate the effect of NOTCH1 deficiency on contractile phenotype and  
25 mitochondrial dynamics of human aortic smooth muscle cells (HAoSMCs).

26 **Results:** Protein analyses of human aortic tissues showed the insufficient expression of NOTCH1  
27 and impaired mitochondrial dynamics in BAV-TAA. HAoSMCs with NOTCH1-knockdown  
28 exhibited reduced contractile phenotype and were accompanied by attenuated mitochondrial  
29 fusion. Furthermore, we identified that mitochondrial fusion activators (leflunomide and  
30 teriflunomide) or mitochondrial fission inhibitor (Mdivi-1) partially rescued the disorders of  
31 mitochondrial dynamics in HAoSMCs derived from BAV-TAA patients.

32 **Conclusions:** The aorta-on-a-chip model simulates the human pathophysiological parameters of  
33 aorta biomechanics and provides a platform for molecular mechanism studies of aortic disease  
34 and related drug screening. This aorta-on-a-chip model and human tissue proteomic analysis  
35 revealed that impaired mitochondrial dynamics could be a potential therapeutic target for BAV-  
36 TAA.

37 **Funding:** National Key R&D Program of China, National Natural Science Foundation of China,  
38 Shanghai Municipal Science and Technology Major Project, Shanghai Science and Technology  
39 Commission, and Shanghai Municipal Education Commission.

## 40 Introduction

41 Bicuspid aortic valve (BAV) disease is the most common congenital cardiovascular abnormality  
42 and is found in nearly 1.4% of the general population (**Garg et al., 2005; Michelena et al., 2011;**  
43 **Verma and Siu, 2014**). BAV arises from incomplete separation or fusion of the aortic valve cusps  
44 and is associated with an approximately 40% risk of developing thoracic aortic aneurysm (TAA),  
45 namely, bicuspid aortopathy (**Verma and Siu, 2014**). BAV-TAA poses a severe health threat to a  
46 large population because progressive aneurysmal dilation can potentially develop into lethal  
47 dissection or rupture (**Goldfinger et al., 2014; Olsson et al., 2006**). The current clinical  
48 management mainly relies on prophylactic surgical repair of the notably dilated aorta (**Coady et**  
49 **al., 2010**). At present, the understanding of pathophysiological mechanisms of BAV-TAA is  
50 incomplete, which leads to the absence of effective pharmaceutical therapy to alleviate  
51 aortopathy progression (**Lindeman and Matsumura, 2019**). Multiple factors, such as genetics  
52 and haemodynamics, are involved in the etiologies of BAV-TAA. In particular, genetic factors are  
53 considered to play a pivotal role in the disease progression (**Isselbacher et al., 2016; Prakash et**  
54 **al., 2014**). NOTCH1 insufficiency has been observed in the population with BAV (**Balistreri et al.,**  
55 **2018; Harrison et al., 2019; Malashicheva et al., 2020; Sciacca et al., 2013**). However, the  
56 underlying mechanism through which insufficient NOTCH1 induces aortopathy remains to be  
57 explored.

58 Mitochondrial dysfunction has been closely linked to a variety of cardiovascular disorders,  
59 such as heart failure and atherosclerosis. Recent studies found that mitochondrial dysfunction  
60 was also related to the development of arterial aneurysm formation (**Cooper et al., 2020; van**  
61 **der Pluijm et al., 2018; Oller et al., 2021**). A single-cell transcriptome analysis on aneurysmal  
62 human aortic tissue suggested that mitochondrial dysfunction and increased chromatin oxidative  
63 phosphorylation (OXPHOS) were found in TAA tissues and insufficient ATP production might not  
64 be sufficient for the contractile activities of human aortic smooth muscle cells (HAoSMCs) (**Li et**  
65 **al., 2020**). Particularly, mitochondrial fission and fusion are dynamically balanced to maintain  
66 mitochondrial homeostasis and functions; and a shift towards fission event is one of the main  
67 causes of mitochondrial dysfunction. In a mice model of abdominal aortic aneurysm (AAA),  
68 impaired mitochondrial dynamics was found to play salient roles in disease development, and  
69 could be attenuated by the mitochondrial fission inhibitor Mdivi1 (**Cooper et al., 2020**). However,  
70 these studies focused on the analysis of abdominal aortic aneurysms and genetic TAA with FBN1  
71 or Fubulin-4 mutation. It has been reported that there was close interaction between NOTCH1  
72 signaling and homeostatic mitochondrial dynamics in the differentiation of cardiomyocytes  
73 (**Kasahara et al., 2013**) and the survival of breast cancer cells (**Chen et al., 2018**). Therefore, the  
74 relationship between NOTCH1 signaling pathway and mitochondrial dynamics in BAV-TAA needs  
75 to be clarified.


76 The traditional TAA animal models are frequently applied for the pathogenesis research and  
77 pharmaceutical therapy, however, not suitable for studying BAV-TAA. Although Koenig et al.  
78 generated NOTCH1-haploinsufficient mice in a preliminary 129S6 background that exhibited  
79 aortic root dilation, these mice did not show BAV characteristics (**Koenig et al., 2017**). Therefore,  
80 these models may not provide sufficient information of pathogenesis and drug response of BAV-  
81 TAA. Owing to the bioengineering advance, microfluidic-based organ-on-chip models have been  
82 widely developed to replicates human tissue microenvironment for toxicity analysis, drug  
83 screening and disease modeling and thus promotes pharmaceutical translation from preclinical  
84 studies to clinical trials (**Zhang et al., 2018; Ingber, 2016; Park et al., 2019; Thacker et al.,**  
85 **2020; Hofemeier et al., 2021**). It provides an opportunity to use a novel platform to study BAV-  
86 TAA on a susceptible human genetic background and may fill the gap between animal and  
87 human medicine. Here, we engineered an *in vitro* organ-on-a-chip model of primary HAoSMCs  
88 that emulates the biomechanics of the human aortic wall. We characterized the association  
89 between mitochondrial dynamics and NOTCH1 deficiency in BAV-TAA on this platform. Our study  
90 provides the first demonstration previously undocumented role of impairment of mitochondrial  
91 fusion in bicuspid aortopathy, which may serve as a potential pharmacological target for  
92 preventing disease progression.

## 93 Results

### 94 The relationship between NOTCH1 insufficiency and mitochondrial dysfunction in human 95 TAA

96 To explore the pathological process involved in BAV-TAA, aortic tissues were collected from six  
97 patients with BAV-TAA who underwent ascending aorta replacement and six patients with non-  
98 diseased aorta who underwent cardiac surgery. The clinical characteristics of the patients are  
99 shown in **Supplementary File-Table I**. Hematoxylin and eosin (H&E) staining showed interrupted  
100 elastic fibers and thinning of the tunica media in the BAV-TAA aortas compared with non-  
101 diseased aortic tissue (**Figure 1a**). A Western blotting analysis showed that NOTCH1 expression  
102 was significantly lower in BAV-TAA aortic tissues than in non-diseased aortic tissues. SM22 and  
103 CNN1 expression was significantly reduced in BAV-TAA aortic tissues (**Figure 1b-c**). We  
104 evaluated the expression of mitochondrial fission- and fusion-related proteins in non-diseased  
105 and BAV-TAA aortic tissues. The results showed that DRP1 and MFF expression was increased  
106 in the BAV-TAA group compared with the non-diseased group, but the differences were not  
107 significant probably due to individual patient differences, which resulted in relatively large protein  
108 expression differences within each group. However, the protein expression of MFN1 and MFN2  
109 was significantly lower in the BAV-TAA group than in the non-diseased group (**Figure 1c**). In  
110 general, we found that MFN1 and MFN2 were expressed at low levels in tissues with NOTCH1  
111 insufficiency (**Figure 1d**). The expression of NOTCH1 exhibited a positive correlation with MFN1  
112 and MFN2 in aortic tissues. The expressions of DRP1 and MFF did not show a correlation with  
113 the expression of NOTCH1 (**Figure 1e**).

114 To further explore the biological differences between non-diseased and BAV-TAA aortic  
115 tissues, a comparative proteomics analysis of global proteins in aortic tissues was performed by  
116 high-performance liquid chromatography tandem mass spectrometry. In total, 70 upregulated  
117 proteins and 257 downregulated proteins were identified (**Supplementary File-Table II**). The  
118 enriched canonical pathways identified by Ingenuity Pathway Analysis (IPA) showed that acute  
119 phase response signaling, mitochondrial dysfunction and oxidative phosphorylation pathways  
120 were significantly enriched in BAV-TAA aortic tissues (**Figure 1f, Supplementary File-Table III**).  
121 In addition, metabolic signaling pathways affecting mitochondrial function, such as the EIF2 and  
122 sirtuin signaling pathways, were also significantly enriched in BAV-TAA. **Figure 1g** and  
123 **Supplementary File-Table III** show the enriched proteins associated with mitochondrial  
124 dysfunction, oxidative phosphorylation pathways, and acute phase response signaling. In total,  
125 seven upregulated proteins and 11 downregulated proteins were found to be related to acute  
126 phase response signaling, and 1 upregulated protein and 10 downregulated proteins were  
127 associated with mitochondrial dysfunction (**Figure 1g, Supplementary File-Table IV**). **Figure 1h**  
128 shows a volcano plot of these 11 differentially expressed proteins that allows visualization of the  
129 fold change and p-value of all differentially expressed proteins between the two groups. MFN1,  
130 MFN2, and NOTCH1 were not detected by mass spectrometry analysis, mainly because the  
131 aortic tissues contain highly cross-linked extracellular matrix that can be refractory to protein  
132 extraction. The publicly available data of the most compressive clinical aortic proteome, up to now,  
133 also indicated the missingness of MFN1, MFN2, DRP1 and NOTCH1 protein in aortic  
134 specimens (**Herrington et al., 2018**).



135  
 136 **Figure 1. The relationship between NOTCH1 insufficiency and mitochondrial dysfunction in BAV-**  
 137 **TAA. (a)** H&E staining of non-diseased and BAV-TAA aortic tissues. The scale bar represents 1 mm in the  
 138 low field and 200 μm in the high field. **(b)** Representative images of the western blotting analysis of the  
 139 expression of NOTCH1, the mitochondrial dynamics proteins DRP-1, MFF, MFN1, and MFN2 and the  
 140 contractile phenotype proteins SM22 and CNN1 in six non-diseased and six BAV-TAA aortic tissue  
 141 fragments. **(c)** Quantification of the total band densities of the proteins normalized to the corresponding band  
 142 density of β-actin (n = 6, \*P < 0.05, two-tailed Student's t tests were used between two groups). **(d)**  
 143 Correlation analysis among the quantified protein expression levels of NOTCH1, MFN1 and MFN2. A  
 144 positive correlation was found between NOTCH1 and MFN1 or MFN2 in aortic tissues. The R<sup>2</sup> between  
 145 NOTCH1 and MFN2 was 0.8069, and that between NOTCH1 and MFN1 was 0.6137. **(e)** Correlation  
 146 analysis between the quantified protein expression of NOTCH1 and DRP1 or MFF. No correlation was found.  
 147 **(f)** The enriched canonical pathways were identified by IPA. Mass spectrometry-based comparative  
 148 proteomics showed that mitochondrial dysfunction and the oxidative phosphorylation pathways were  
 149 significantly enriched in BAV-TAA aortic tissues. **(g)** Heatmap of the expression of enriched proteins  
 150 involved in mitochondrial dysfunction, the oxidative phosphorylation pathways and acute phase response  
 151 signaling. **(h)** Volcano plot visualization of the differentially expressed proteins related to mitochondrial  
 152 dysfunction. The colors indicate the following: gray, no differential expression; red, upregulated proteins; and  
 153 blue, downregulated proteins. The proteins related to mitochondrial dysfunction are labeled. All the data are  
 154 expressed as the means ± SDs.

155 The online version of this article includes the following source data for figure 1:

156 **Source data 1.** The original raw data for western blotting.

157 **Source data 2.** List of total differential protein expression between non-diseased and BAV-TAA aortic tissues.


158 **Source data 3.** The total enriched canonical pathways in BAV-TAA aortic tissues.

159 **Source data 4.** List of total protein expression between non-diseased and BAV-TAA aortic tissues.

## 160 **Construction of aorta-on-a-chip model**

161 During cardiac systolic and diastolic cycles, the thoracic aortic wall experiences rhythmic tensile  
162 strain. Previous clinical studies have shown that the circumferential strains of the aortic wall range  
163 from low values of  $7.0 \pm 2.5\%$  to high values of  $21.5 \pm 12.4\%$ , and these can be further influenced  
164 by age, the aortic diameter, and the presence of aortopathy (**Akazawa et al., 2016; Bell et al.,**  
165 **2014**). To better simulate the rhythmic tensile strain experienced by HAoSMCs *in vivo*, we  
166 developed a compact microfluidic aorta-on-a-chip model with commercialized highly flexible  
167 polydimethylsiloxane (PDMS) membranes (**Figure 2a**). The model was composed of three  
168 chambers: i) a top vacuum chamber deforming the upper PDMS membrane; ii) a middle chamber  
169 containing the culture medium to maintain cell growth on the PDMS membranes; and iii) a bottom  
170 vacuum chamber deforming the lower PDMS membrane. HAoSMCs were cultured on the PDMS  
171 membranes in the middle cell culture chamber. The dimensions of the model are shown in **Figure**  
172 **2—figure supplement 1a**. Young's modulus of the commercialized PDMS membrane shows  
173 excellent homogeneity and tensile properties (**Figure 2—figure supplement 1b**). The rhythmic  
174 tensile strain was generated by connecting the top and bottom chambers to a vacuum pump that  
175 cyclically deformed the PDMS membrane. The rhythm and value of the dynamic negative  
176 pressure in the chambers were controlled by a set of apparatuses consisting of a monochip  
177 computer, a pressure regulator and a solenoid valve.

178 To quantify the tensile strains of the PDMS membrane generated by negative pressure in a  
179 vacuum chamber, we captured the real-time deformations of the PDMS membranes and  
180 measured the changes in length. With vacuum pressures of 0 kPa, 10 kPa, and 15 kPa, the  
181 dynamic deformations of the PDMS membranes were recorded from a cross-sectional view of the  
182 microfluidic model (**Figure 2b**). The two deformations of the upper and lower PDMS membranes  
183 were coincident in terms of amplitudes and rhythms (**Figure 2c**). A vacuum pressure of 10 kPa  
184 induced  $7.18 \pm 0.44\%$  strain ( $7.09 \pm 0.18\%$  strain in the lower layer and  $7.27 \pm 0.28\%$  strain in the  
185 upper layer), and 15 kPa induced  $17.28 \pm 0.91\%$  strain ( $17.29 \pm 0.62\%$  strain in the lower layer  
186 and  $17.23 \pm 0.64\%$  strain in the upper layer) (**Figure 2c and Figure 2—figure supplement 1c**).  
187 To replicate different strains on the human aortic wall, we applied  $7.18 \pm 0.44\%$  strain induced by  
188 a vacuum pressure of 10 kPa as a relatively low strain and  $17.28 \pm 0.91\%$  strain induced by a  
189 vacuum pressure of 15 kPa as a relatively high strain.



190  
 191 **Figure 2. Schematic design and strain characterization of the aorta-on-a-chip model.** (a) Schematic  
 192 overview of the in vitro chip model. (b) Cross-sectional view of the microfluidic aorta-on-a-chip model  
 193 showing the deformations of the PDMS membranes under different vacuum pressures. The scale bar  
 194 represents 5 mm. (c) Measured tensile strains of the upper (red) and lower (blue) membranes at negative  
 195 pressures of 10 kPa and 15 kPa for five cycles. The peak tensile strain per cycle averaged  $7.18 \pm 0.44\%$   
 196 with a cyclic negative pressure of 10 kPa and  $17.28 \pm 0.91\%$  with a cyclic negative pressure of 15 kPa.

197 The online version of this article includes the following figure supplement(s) and source data for figure 2:


198 **Figure supplement 1.** Characterization and parameters of the aorta-on-a-chip model.

199 **Source data 1.** The raw data of PDMS membrane Young's modulus.

200 **Source data 2.** The quantification data for measurement of tensile strains of the upper and lower  
 201 membranes.

## 202 **Rhythmic tensile strain defines cell alignment and enhances cell contractility**

203 To identify the effect of rhythmic tensile strain on the contractility of HAoSMCs, the changes in  
 204 cellular morphology, alignment and contractile/synthetic phenotypic markers were assessed  
 205 under rhythmic low/high strain or static conditions (**Figure 3a**). Cytoskeletal F-actin staining  
 206 images of HAoSMCs showed a decrease in the cell width and an increase in the cell length in the  
 207 presence of rhythmic low or high strain (**Figure 3b**). The results also revealed an increase in the  
 208 length-to-width ratio from  $2.33 \pm 0.82$  under static conditions to  $2.74 \pm 1.01$  under low strain or  
 209  $3.50 \pm 1.19$  under high strain (**Figure 3c**). Compared with the irregular orientation of the cells  
 210 observed under static culture, the cells tended to align perpendicularly to the direction of the  
 211 applied strain. The angle between the directions of the cellular alignment and the applied strain  
 212 was approximately  $90^\circ$  (**Figure 3d**). To evaluate the effect of rhythmic tensile strain on the  
 213 expression of phenotypic markers, the protein levels of SM22, CNN1 and OPN in HAoSMCs were  
 214 measured by western blotting. The results showed that the contractile phenotypic markers SM22  
 215 and CNN1 were upregulated under either low or high strain (**Figure 3e-f**). The expression of the  
 216 synthetic phenotypic marker OPN under both rhythmic low and high strain was lower than that  
 217 observed under static conditions. These results indicate that the application of rhythmic strain can  
 218 induce HAoSMCs to spread to longer shapes, align unidirectionally, and exhibit enhanced  
 219 contractility on the chip model.



220

221 **Figure 3. Effect of rhythmic strain on the cell morphology, alignment and phenotype.** (a) Schematic  
222 workflow of cell culture on the chip model. (b) Representative images of cytoskeletal F-actin staining of  
223 HAoSMCs exposed to low or high rhythmic strain for 24 hrs. The scale bar represents 200 μm. (c) Length-  
224 to-width ratio of HAoSMCs after exposure to low or high rhythmic strain for 24 hrs. (n = 3, cells were  
225 measured in three fields per sample, data from every single cell were plotted. \*\*\*\* $P < 0.0001$ , one-way  
226 ANOVA followed by Tukey's post hoc test). (d) Alignments of HAoSMCs exposed to low or high rhythmic  
227 strain for 24 hrs. (e) Representative images of the western blotting analyses of protein markers of the  
228 contractile phenotype (SM22 and CNN1) and synthetic phenotype (OPN) of HAoSMCs after exposure to low  
229 or high rhythmic strain for 24 hrs. (f) Quantification of the total band densities for individual proteins  
230 normalized to the corresponding band of β-actin (n = 4, \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ ,  
231 one-way ANOVA followed by Tukey's post hoc test). All the data are expressed as the means ± SDs.

232 The online version of this article includes the following source data for figure 3:

233 **Source data 1.** The quantification data for cell length-to-width ratio.

234 **Source data 2.** The quantification data for orientation of the cells.

235 **Source data 3.** The original raw data for western blotting.


### 236 Contractility and mitochondrial dynamics in NOTCH1-insufficient HAoSMCs

237 To clarify the effect of NOTCH1 insufficiency on HAoSMC contractility, we cultured NOTCH1-  
238 insufficient cells under rhythmic low or high strain or static conditions and then characterized the  
239 expression of phenotypic markers. The schematic workflow of the experimental design is shown  
240 in **Figure 4a**. First, NOTCH1 was knocked down in HAoSMCs using a lentivirus expressing short  
241 hairpin RNA (shRNA) targeting NOTCH1 (**Shao et al., 2015**). To evaluate the effect of the  
242 lentivirus vector on NOTCH1 and phenotypic markers, HAoSMCs without any treatments (WT),  
243 HAoSMCs treated with negative control shRNA (NC) and HAoSMCs treated with NOTCH1  
244 shRNA (NOTCH1-KD) were verified using quantitative real-time PCR and western blotting  
245 experiments. An approximately 60% reduction in NOTCH1 mRNA expression was found in the  
246 NOTCH1-KD group compared with the WT and NC groups (**Figure 4—figure supplement 1a**).  
247 Under static conditions, the mRNA expression of SM22 and CNN1 was upregulated and that of  
248 OPN was downregulated in the NOTCH1-KD group compared with the WT and NC groups  
249 (**Figure 4—figure supplement 1a**). The same tendency was found for the protein expression  
250 levels by western blotting analysis (**Figure 4—figure supplement 1b-c**).

251 NOTCH1-KD and WT HAoSMCs were cultured on aorta-on-chip models under rhythmic  
252 strain and static conditions to characterize the expression of SM22 and CNN1. As shown in



253 **Figure 4b-c**, immunofluorescent staining images showed that SM22 and CNN1 were upregulated  
 254 in the NOTCH-KD group compared with the WT group under static conditions. However, the  
 255 opposite results were observed under rhythmic strain conditions: the expression of SM22 and  
 256 CNN1 in NOTCH-KD HAoSMCs was lower than that in the WT group under rhythmic strain  
 257 conditions. Western blotting analyses revealed similar alterations in the expression of SM22 and  
 258 CNN1 (**Figure 4d-e**). In WT HAoSMCs, rhythmic strain induced the upregulation of SM22 and  
 259 CNN1 expression compared with the levels observed under static conditions. However, a  
 260 downregulation of SM22 and CNN1 expression was detected in NOTCH-KD HAoSMCs exposed  
 261 to rhythmic strain. These results suggested that rhythmic strain induced different effects between  
 262 WT and NOTCH-KD HAoSMCs. In NOTCH-KD HAoSMCs, SM22 and CNN1 expression were  
 263 higher under static conditions and lower under rhythmic strain than those in WT HAoSMCs.



264

265 **Figure 4. Phenotypic switching of NOTCH1-insufficient HAoSMCs under static and rhythmic strain**  
 266 **conditions.** (a) Schematic workflow of NOTCH1-KD HAoSMCs on the chip model. (b) Representative  
 267 images of immunofluorescence staining of SM22 and CNN1 after exposure to rhythmic low or high strain for  
 268 24 hrs. The scale bar represents 200 μm. (c) Intensity of immunofluorescence staining of SM22 and CNN1  
 269 (n=3, data from three independent biological replicates each with two to four technical replicates were  
 270 plotted. \**P* < 0.05, \*\**P* < 0.01, \*\*\*\**P* < 0.0001, two-way ANOVA followed by Tukey's post hoc test). (d)  
 271 Representative images of the western blotting analyses of SM22 and CNN1 in the WT and NOTCH1-KD  
 272 groups exposed to rhythmic low or high strains for 24 hrs. (e) Quantification of the total band densities for  
 273 individual proteins normalized to the corresponding band density of β-actin (n = 4, \*\**P* < 0.01, \*\*\**P* < 0.001,  
 274 \*\*\*\**P* < 0.0001, two-way ANOVA followed by Tukey's post hoc test). All the data are expressed as the  
 275 means ± SDs.

276

The online version of this article includes the following figure supplement(s) and source data for figure 4:

277

**Figure supplement 1.** Alteration of NOTCH1 signaling, phenotype and mitochondrial dynamics in HAoSMCs after NOTCH1 shRNA transfection.

278

**Source data 1.** The data for intensity of immunofluorescence staining of SM22 and CNN1.


279

**Source data 2.** The original raw data for western blotting.

280

281 Furthermore, we assessed the alterations in mitochondrial function and dynamics in  
282 NOTCH1-KD HAoSMCs. Specifically, western blotting was performed to detect the protein  
283 expression of MFN1 and MFN2 (mitochondrial fusion-related proteins) and DRP1 and MFF  
284 (mitochondrial fission-related proteins). No significant difference in MFN1, MFN2, DRP1 and MFF  
285 protein expression was found between the WT and NC groups under static conditions, which  
286 suggested that the expression of these mitochondrial dynamics-related proteins was not affected  
287 by the lentivirus vector (**Figure 4—figure supplement 1d-e**). As shown in **Figure 5a-b**, the  
288 expression of MFN1 and MFN2 was downregulated in NOTCH1-KD HAoSMCs under static  
289 conditions, and the expression of MFN2 presented a significant difference between the two  
290 groups. DRP1 and MFF expression was significantly increased in NOTCH1-KD HAoSMCs under  
291 static conditions. Rhythmic strain induced a decrease in MFN1 expression in the NOTCH1-KD  
292 group but an increase in the WT group. MFN2 expression was decreased in both the WT and  
293 NOTCH1-KD groups after exposure to rhythmic strain but was lower in the NOTCH1-KD group  
294 than in the WT group, particularly under rhythmic high strain conditions. Rhythmic strain induced  
295 an increase in DRP1 and MFF expression in both the WT and NOTCH1-KD groups, and DRP1  
296 and MFF were highly expressed in NOTCH1-KD HAoSMCs under both rhythmic strain and static  
297 conditions (**Figure 5b**). The fragmented mitochondrial morphology observed in NOTCH1-KD  
298 HAoSMCs under rhythmic strain conditions indicated decreased mitochondrial fusion, increased  
299 mitochondrial fission, i.e., impaired mitochondrial dynamics. As shown in **Figure 5c**, MitoTracker  
300 staining of the mitochondrial shape indicated elongated and interconnected mitochondrial  
301 networks in both WT and NOTCH1-KD groups under static conditions. Low or high strain induced  
302 alterations of the mitochondrial shape in both WT and NOTCH1-KD HAoSMCs, and these  
303 alterations included both a decrease in long rod-shaped elongated interconnected mitochondrial  
304 networks and a significant increase in spheroid-shaped fragmented mitochondrial morphology  
305 and were more frequent in NOTCH1-KD HAoSMCs under high strain conditions (**Figure 5c-d**).

306 Mitochondrial dynamics play an important role in the maintenance of normal mitochondrial  
307 function. As shown in **Figure 5e-f**, the fluorescence intensity of the tetramethylrhodamine methyl  
308 ester perchlorate (TMRM) staining, which reflects the mitochondrial membrane potential, was  
309 lower in NOTCH1-KD HAoSMCs than in the WT group under rhythmic strain. These results  
310 indicated loss of mitochondrial membrane potential in NOTCH1-KD HAoSMCs under rhythmic  
311 strain. The mitochondrial superoxide (MitoSOX) staining of NOTCH1-KD HAoSMCs was  
312 significantly higher than that of the WT group under rhythmic strain (**Figure 5g-h**), which  
313 indicated that ROS production was increased in NOTCH1-KD HAoSMCs under rhythmic strain  
314 conditions. As an energy source of cells synthesized by mitochondria, the ATP concentration was  
315 also evaluated. Rhythmic strain increased the ATP concentration in both WT and NOTCH1-KD  
316 HAoSMCs, but under rhythmic strain conditions, a lower ATP concentration was found in  
317 NOTCH1-KD HAoSMCs than in WT HAoSMCs (**Figure 5i**). No significant difference in the TMRM  
318 or MitoSOX fluorescence intensity or ATP concentration was found between WT and NOTCH1-  
319 KD HAoSMCs under static conditions, which indicated that NOTCH1 insufficiency did not affect  
320 mitochondrial function under static conditions. Taken together, these data indicated that NOTCH1  
321 insufficiency could induce mitochondrial dysfunction in HAoSMCs by reducing mitochondrial  
322 fusion, inducing loss of mitochondrial membrane potential, increasing ROS production and  
323 generating insufficient ATP under rhythmic strain, and these effects are accompanied by an  
324 impaired contractile phenotype. These findings were consistent with previous studies showing  
325 that imbalanced mitochondrial dynamics could induce VSMC dedifferentiation into the synthetic  
326 phenotype (**Salabei and Hill, 2013**).



327

328 **Figure 5. Effect of NOTCH1 insufficiency on mitochondrial dynamics and function in HAoSMCs.** (a)  
 329 Representative images of the western blotting analyses of MFN1, MFN2, DRP1 and MFF expression in the  
 330 WT and NOTCH1-KD groups under rhythmic low or high strain or static conditions. (b) Quantification of the  
 331 total band densities for four individual proteins normalized to the corresponding band density of  $\beta$ -actin ( $n =$   
 332 4,  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ ,  $****P < 0.0001$ , two-way ANOVA followed by Tukey's post hoc test).  
 333 (c) MitoTracker staining images of the mitochondrial morphologies in the WT and NOTCH1-KD groups  
 334 under rhythmic low or high strain or static conditions. The scale bar represents 50  $\mu\text{m}$ . (d) Quantification of  
 335 the mitochondria length ( $n = 3$ ,  $**P < 0.01$ ,  $****P < 0.0001$ , two-way ANOVA followed by Tukey's post hoc  
 336 test). (e) TMRM staining of the mitochondrial membrane potentials in the WT and NOTCH1-KD groups  
 337 under rhythmic low or high strain or static conditions. The scale bar represents 100  $\mu\text{m}$ . (f) Quantification of  
 338 the relative TMRM fluorescence intensity ( $**P < 0.01$ , two-way ANOVA followed by Tukey's post hoc test). (g)  
 339 MitoSOX staining of mitochondrial superoxide generation in the WT and NOTCH1-KD groups. The scale bar  
 340 represents 100  $\mu\text{m}$ . (h) Quantification of the relative MitoSOX fluorescence intensity ( $n=3$ , data from three  
 341 independent biological replicates each with two to three technical replicates were plotted.  $*P < 0.05$ ,  $**P <$   
 342  $0.01$ , two-way ANOVA followed by Tukey's post hoc test). (i) The ATP concentrations were measured using  
 343 an ATP Determination Kit ( $n=3$ , data from three independent biological replicates each with two technical  
 344 replicates were plotted.  $**P < 0.01$ , two-way ANOVA followed by Tukey's post hoc test). Quantitative  
 345 measurements were calculated using ImageJ software. All the data are expressed as the means  $\pm$  SDs.

346 The online version of this article includes the following source data for figure 5:

347 **Source data 1.** The quantification data for mitochondria length.

348 **Source data 2.** The quantification data for relative TMRM fluorescence intensity.

349 **Source data 3.** The quantification data for relative MitoSOX fluorescence intensity.

350 **Source data 4.** The data for ATP concentrations.

351 **Source data 5.** The original raw data for western blotting.

352


353

354 **Drugs rescued the impairment of mitochondrial dynamics in NOTCH1-insufficient**  
355 **HAoSMCs from BAV-TAA**

356 To confirm whether the decreased contractile phenotype of NOTCH1-knockdown HAoSMCs can  
357 be rescued by inhibition of mitochondrial fission or activation of mitochondrial fusion, we  
358 evaluated the phenotypic alterations and mitochondrial dynamics of NOTCH1-insufficient  
359 HAoSMCs treated with a mitochondrial fission inhibitor (Mdivi-1) or mitochondrial fusion activators  
360 (leflunomide or teriflunomide) under rhythmic high-strain conditions. A schematic workflow of the  
361 drug screening experiments was shown in **Figure 6a**. HAoSMCs purchased from ATCC  
362 (CRL1999), primary HAoSMCs (p-HAoSMCs) isolated from patients in the non-diseased group  
363 and p-HAoSMCs purchased from ATCC (PCS-100-012) were transfected with NOTCH1-shRNA  
364 to generate NOTCH1-knockdown HAoSMCs.

365 The effect of drug testing on aorta-on-a-chip model was desirable, even though the results  
366 did not exhibit all the positive responses. In the CRL1999 HAoSMCs (**Figure 6b**), all three drugs  
367 enhanced MFN1 and MFN2 expression to different extents, and the greatest increase in MFN1  
368 expression was obtained with Mdivi-1. In addition, the three drugs all decreased DRP1  
369 expression to different extents but did not affect MFF expression. The three drugs also increased  
370 SM22 and CNN1 expression to different extents, and the maximal expression of SM22 and CNN1  
371 was obtained with leflunomide. In p-HAoSMCs isolated from patients in the non-diseased group  
372 (**Figure 6c**), the three drugs increased MFN1 expression, but no significant difference was found  
373 compared with the control group. Teriflunomide significantly increased MFN2 and DRP1  
374 expression and significantly decreased MFF expression. Although the effects of these drugs on  
375 mitochondrial dynamics were not desirable, all three drugs increased the expression of SM22 and  
376 CNN1 to different extents. In PCS-100-012 p-HAoSMCs (**Figure 6d**), none of the three drugs  
377 exerted an obvious effect on MFN1, MFN2 and DRP1 expression, and teriflunomide significantly  
378 decreased MFF expression. All three drugs increased the expression of SM22 and CNN1 to  
379 different extents.

380 To further evaluate the potential of these drugs for clinical use in the treatment of NOTCH1-  
381 insufficient patients with BAV-TAA, we isolated p-HAoSMCs from the aortic tissues of three  
382 individual patients with BAV-TAA. The clinical characteristics of three patients with BAV-TAA are  
383 shown in **Supplementary File-Table V**. Significantly lower NOTCH1 protein expression was  
384 found in p-HAoSMCs from BAV-TAA aortic tissues compared with p-HAoSMCs from non-  
385 diseased aortic tissue (**Figure 6—figure supplement 1**). A significant reduction in MFN1 and  
386 MFN2 expression was found in p-HAoSMCs from BAV-TAA aortic tissues under static and  
387 rhythmic high-strain conditions. We also found that SM22 and CNN1 expression was significantly  
388 reduced in p-HAoSMCs from BAV-TAA aortic tissues under rhythmic high-strain conditions  
389 (**Figure 6—figure supplement 1**). The three drugs exerted different effects on mitochondrial  
390 dynamics-related proteins (**Figure 6e-g**). All three drugs enhanced MFN2 expression to different  
391 extents, and maximal MFN2 expression was obtained with the treatment of teriflunomide. The  
392 three drugs increased MFN1 expression and decreased DRP1 expression to different extents in  
393 two lines of BAV-TAA p-HAoSMCs, and the greatest decrease in DRP1 expression was obtained  
394 with teriflunomide. The three drugs decreased MFF expression to different extents in the two lines  
395 of BAV-TAA p-HAoSMCs and exerted different effects on the expression of the contractile  
396 proteins SM22 and CNN1, and teriflunomide significantly increased SM22 expression in the two  
397 lines of BAV-TAA p-HAoSMCs. All three drugs enhanced CNN1 expression to different extents,  
398 and Mdivi-1 or teriflunomide significantly increased CNN1 expression in one line of BAV-TAA p-  
399 HAoSMCs. The data from BAV-TAA p-HAoSMCs indicated that teriflunomide exerted a more  
400 obvious effect on rescuing impaired mitochondrial dynamics and the expression of the contractile  
401 phenotype proteins SM22 and CNN1 under rhythmic high-strain conditions. These results  
402 indicated that leflunomide, Mdivi-1, and, in particular, teriflunomide, could serve as drug  
403 candidates for ameliorating the disease progression of BAV-TAA.



404

405 **Figure 6. Screening of drugs that can rescue the cell phenotype and mitochondrial dynamics using**  
 406 **the chip model.** (a) Schematic workflow of the experimental design. After treatment with treated with Mdivi-  
 407 1, leflunomide and teriflunomide on the chip models with (b) a NOTCH1-knockdown HAoSMC cell line  
 408 (CRL1999), (c) NOTCH1-knockdown p-HAoSMCs isolated from non-diseased aortic tissues, (d) NOTCH1-  
 409 knockdown p-HAoSMCs purchased from ATCC, and (e-g) p-HAoSMCs isolated from aortic tissues from  
 410 three patients with BAV-TAA, quantification of the total band densities of the mitochondria-related proteins  
 411 MFN1, MFN2, DRP-1, and MFF and the contractile phenotype proteins SM22 and CNN1 were normalized to  
 412 the corresponding band densities of  $\beta$ -actin. All the data are expressed as the means  $\pm$  SDs.  $n = 3$ , \* $P <$   
 413  $0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ , one-way ANOVA followed by Tukey's post hoc test.

414

The online version of this article includes the following figure supplement(s) and source data for figure 6:

415

**Figure supplement 1.** Expression NOTCH1, phenotype and mitochondrial dynamics related proteins in

416

p-HAoSMCs from BAV-TAA aortic tissues.

417

**Source data 1.** The original raw data for western blotting.

418

419

## Discussion

420

In this study, protein analyses of human aortic aneurysm tissues suggested the insufficient  
 421 expression of NOTCH1 in BAV-TAA was associated with the impaired mitochondrial dynamics  
 422 and OXPHOS. To verify it, we established a microfluidic aorta-on-a-chip model that enabled us to  
 423 reproducibly generate the rhythmic tensile strain of the native human aortic wall. We showed that  
 424 this model could apply a biomimetic rhythmic tensile strain with a confined amplitude/magnitude  
 425 and rhythm to HAoSMCs. We also confirmed that impaired mitochondrial fusion contributed to the

426 attenuated contractile phenotype observed in NOTCH1-KD HAoSMCs. We further identified that  
427 MFN1/2 agonists and DRP1 inhibitors were able to reverse the imbalance in mitochondrial  
428 dynamics and partly rescue the contractile phenotype in NOTCH1-insufficient HAoSMCs.

429 The majority of studies on the molecular mechanism and pharmacotherapy for TAA have  
430 been conducted using conventional cell culture models and animal models. The  
431 pathophysiological features of human aortic aneurysm can be induced in animal models by  
432 elastase, calcium chloride, angiotensin II or transgenesis, which partially enable investigation of  
433 the etiology, pathogenesis, and therapeutic targets of TAA at an early stage (**Eckhouse et al.,**  
434 **2013; Ikonomidis et al., 2003; Mao et al., 2015**). However, all these animal models cannot  
435 replicate the native characteristics of BAV-TAA. Moreover, the apparent species gap between  
436 preclinical animal experiments and clinical studies might also impede pharmaceutical discovery  
437 (**Lindeman and Matsumura, 2019**). In contrast, the shortcoming of the conventional cell culture  
438 model of aortic disease lies in its inability to recapitulate *in vivo* biomechanical stimuli. Advances  
439 in microfabrication and microfluidics have provided novel techniques for building organ-on-a-chip  
440 models that integrate rhythmic tensile strains into *in vitro* cell culture. Organ-on-a-chip models can  
441 be broadly defined as any form of microfabricated cell culture device that models organ-specific  
442 biochemical and physical microenvironments (**Zhao et al., 2019; Park et al., 2019**) and represent  
443 an *in vitro* platform that is complementary to animal models. By anatomizing the complexity of the  
444 biomechanical microenvironment, this study focused on the physiological rhythmic strain on  
445 HAoSMCs in the aortic tunica media, which plays a central role in the pathogenesis of aneurysms.  
446 In particular, the strain of the ascending aorta, which was defined as the maximal change in the  
447 ascending aorta diameter over a cardiac cycle, can vary diversely from a low value of  $7.0 \pm 2.5\%$   
448 to a high value of  $21.5 \pm 12.4\%$  depending on age, sex and disease severity (**Akazawa et al.,**  
449 **2016; Bell et al., 2014; Morrison et al., 2009**). Under rhythmic strain, healthy HAoSMCs  
450 maintain a contractile phenotype, which allows regulation of the vascular tone. While, diseased  
451 HAoSMCs dedifferentiate into a synthetic phenotype under pathological conditions, and this  
452 dedifferentiation represents the initial step toward an aneurysm pathology (**Petsophonsakul et**  
453 **al., 2019**). The aorta-on-a-chip model developed in this study featured the controlled magnitude  
454 and rhythm of mechanical stimuli relevant to the human pathophysiological parameters of aorta  
455 biomechanics.

456 NOTCH1 has an important role in the maintenance of normal mitochondrial dynamics.  
457 Previous studies have reported that the expression of NOTCH1 signaling was attenuated in the  
458 aortic tissues of patients with BAVs (**Sciacca et al., 2013**). Additionally, Balistreri et al. found  
459 decreased mRNA levels of NOTCH1-4 in aortic aneurysm tissues and decreased protein levels of  
460 soluble NOTCH1 in plasma (**Balistreri et al., 2018**). Using clinical samples, our protein analysis  
461 also indicated that patients with BAV-TAA presented lower expression of NOTCH1 protein in  
462 ascending aortic aneurysms; and the NOTCH1 insufficiency was accompanied with attenuated  
463 mitochondrial fusion. This was consistent with the previous studies that reported NOTCH1  
464 regulates mitochondria dynamics in cardiovascular cell differentiation and survival. Kasahara et al.  
465 found that mitochondrial fusion regulates the differentiation of myocardial cells through NOTCH1  
466 signaling pathway (**Kasahara et al., 2013**). Here, we found that NOTCH1 insufficiency induced  
467 mitochondrial dysfunction in HAoSMCs by reducing mitochondrial fusion, along with loss of  
468 mitochondrial membrane potential, increasing ROS production and generating insufficient ATP  
469 under rhythmic strain. These results indicated that the relationship between impaired  
470 mitochondrial fusion and NOTCH1 deficiency in BAV-TAA. Consistently, we found decreased  
471 contractile phenotype in NOTCH1-deficient HAoSMCs under rhythmic tensile strain and in BAV-  
472 TAA aortic tissues, accompanied by lower NOTCH1 expression and impaired mitochondrial  
473 fusion.

474 NOTCH1 signaling is also involved in the regulation of HAoSMCs differentiation and the  
475 expression of contractile proteins. HAoSMCs are highly plastic cells and undergo reversible  
476 changes in phenotype in response to environmental stimuli (**Vasquez-Trincado et al., 2016**).  
477 Differentiated HAoSMCs have a contractile phenotype with little proliferation and little secretion of  
478 extracellular matrix. HAoSMCs transform from a contractile into a synthetic phenotype and induce

479 loose of vascular tone, which is one of the major pathological process in TAA. In this study, we  
480 found that NOTCH1 insufficiency in HAoSMCs downregulated the contractile phenotype proteins  
481 SM22 and CNN1 under rhythmic strain. Also, the expressions of SM22 and CNN1 were  
482 decreased in BAV-TAA aortic tissues compared to non-diseased aortic tissues. Nosedá et al.  
483 reported that NOTCH1 activation was needed for expression of the contractile phenotype protein  
484  $\alpha$ SMA in VSMCs *via* the NOTCH/CSL axis (**Nosedá et al., 2006**). High et al. reported that  
485 NOTCH1 promotes the differentiation of the cardiac neural crest into differentiated VSMCs and  
486 the expression of  $\alpha$ SMA (**High et al., 2007**). However, the specific mechanism by which NOTCH1  
487 leads to a reduced contractile phenotype has not been fully investigated. Based on results  
488 obtained from the aorta-on-a-chip model, it comes to the assumption that NOTCH1-insufficiency  
489 reduced the contractile phenotype through decreasing mitochondrial fusion.

490 Mitochondrial dynamics itself has been recognized as one of the critical factors that regulate  
491 the phenotype switching of vascular smooth muscle cells (VSMCs). Salabei and Hill reported that  
492 PDGF-BB induces the dedifferentiation of VSMCs into the synthetic phenotype through  
493 overactivation of mitochondrial fission (**Salabei and Hill, 2013**). Chen et al. found that the  
494 expression of MFN2 is markedly reduced in hyperproliferative VSMCs from spontaneously  
495 hypertensive rat arteries (**Chen et al., 2004**). Using the aorta-on-a-chip model, we demonstrated  
496 the decreased mitochondrial fusion in NOTCH1-insufficient HAoSMCs, accompanied with  
497 decreased contractile phenotypes. Thus, mitochondrial dynamics regulated by NOTCH1 may  
498 have a role in maintains of contractile phenotype. In addition, we also found the contractile  
499 phenotype was upregulated in NOTCH1-insufficient HAoSMCs after treatment with mitochondrial  
500 fusion activators and mitochondrial fission inhibitors, which further verified the hypothesis that  
501 contractile phenotype of HAoSMCs was regulated by NOTCH1-mitochondrial fusion axis. In  
502 clinical samples, our protein analysis indicated that aortic tissues from patients with BAV-TAA  
503 presented the reduced expressions of mitochondrial fusion proteins and contractile phenotype  
504 proteins, compared with non-diseased aortic tissues. Further, the mass spectrometry-based  
505 proteomic analysis of aortic tissue samples indicated that mitochondrial dysfunction and  
506 OXPHOS pathways were significantly altered in BAV-TAA aortic tissues. Consistent with the  
507 previous single-cell transcriptome analysis, TAA aortic tissues showed decreased mitochondrial  
508 function; and this finding suggests that OXPHOS ATP production might be insufficient for VSMC  
509 contractile activities (**Li et al., 2020**). Therefore, maintaining normal mitochondrial dynamics *via*  
510 NOTCH1 could be one of the mechanisms through which NOTCH1 regulates HAoSMCs's  
511 contractility and maintains vascular wall tension. However, the specific mechanism by which  
512 reduced mitochondrial fusion causes a reduction in the contractile phenotype requires further  
513 investigation. In addition, our proteomic analysis of tissue samples showed that several  
514 mitochondrial dysfunction-related pathways, namely, EIF2 signaling and the sirtuin signaling  
515 pathway, were also altered in BAV-TAA aortic tissue, which may provide research directions to  
516 investigate further mechanisms.

517 Lastly, we demonstrated that MFN1/2 agonists and DRP1 inhibitors reversed the imbalanced  
518 mitochondrial dynamics in BAV-TAA p-HAoSMCs with intrinsic NOTCH1 insufficiency or in  
519 NOTCH1-KD HAoSMCs on the aorta-on-a-chip model, which provides a prototype for an *in vitro*  
520 drug testing platform. Two FDA-approved drugs, leflunomide or teriflunomide, rescued the  
521 contractile phenotype of BAV-TAA p-HAoSMCs and showed their potential to ameliorate disease  
522 progression. Zorzano's group first found that dihydroorotate dehydrogenase inhibitors  
523 (leflunomide, teriflunomide, or brequinar sodium) could promote mitochondrial elongation through  
524 induction of the mitochondrial proteins MFN1 and MFN2 in HeLa cells (**Miret-Casals et al., 2018**).  
525 The experimental data obtained in this study encourage further studies on the application of  
526 leflunomide and teriflunomide in BAV-TAA.

527 In conclusion, we constructed a aorta-on-a-chip model, which could serve as a  
528 complementary tool to the current cell culture system and animal models. Using the aorta-on-a-  
529 chip model, we found that NOTCH1 insufficiency in HAoSMCs induced phenotypic switching from  
530 a contractile to a synthetic phenotype accompanied by an impairment of mitochondrial fusion,  
531 implying its potential role as a therapeutic target for BAV-TAA. At the current stage, *in vitro*

532 microphysiological models and animal models are complementary to each other in the sense that  
533 they are able to provide more comprehensive basis for preclinical assays with greater predictive  
534 power.

## 535 **Materials and Methods**

### 536 **Aorta-on-a-chip model design and fabrication**

537 The structure of the three-layer microfluidic aorta-on-a-chip model was designed using computer-  
538 aided design (CAD) software (Autodesk Inc). The size of the three layers were 100 mm × 40 mm  
539 × 6 mm. The top and bottom layers had microchannels with dimensions of 70 mm × 6 mm × 4  
540 mm, and the middle layer contained a microchannel with dimensions of 70 mm × 6 mm × 6 mm.  
541 Molds of the three layers were custom-made using a high-precision computer numerical control  
542 (CNC) engraving machine (Jingyan Technology). The frame of the molds and the microchannels  
543 were carved out of polymethyl methacrylate (PMMA) plates, which were then glued on another  
544 PMMA plate. Polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning) was polymerized in  
545 defined casts at a weight ratio of base to curing agent of 10:1. The mixed PDMS was poured into  
546 the molds and underwent cross-linking at 70°C for 2 hrs. Commercialized PDMS membranes  
547 were purchased from Hangzhou Bald Advanced Materials (thickness, 200 ± 2 μm; Young's  
548 modulus, 1.7 MPa). Subsequently, the three PDMS layers were peeled off the molds. The bottom  
549 layer of the PDMS slab was bonded with one PDMS membrane after oxygen plasma treatment  
550 (Harrick Plasma), and the top PDMS layer was bonded to another PDMS membrane in a similar  
551 manner. The middle PDMS layer was then sandwiched between the top and bottom membranes;  
552 this step was performed under a microscope to guarantee that the upper and lower  
553 microchannels fully overlapped with the middle microchannel.

### 554 **Mechanical stimulation**

555 The cells were stretched by applying different percentages of rhythmic strain to the PDMS  
556 membranes for 24 hrs. The vacuum pump was connected to a water-oil separator, which dried  
557 the gas to protect the downstream vacuum regulator and solenoid valve. The inlet of the vacuum  
558 pumps was then connected to the computer-controlled solenoid system by applying rhythmic  
559 stretching at a frequency of 1 Hz and then connected to the gas channel of the aorta-on-a-chip  
560 model. The regulator was used to control the vacuum magnitude. The solenoid valve was a  
561 voltage-dependent on/off valve used to control the stretching frequency of the PDMS membrane.  
562 When the supply voltage was greater than 24 V, the gas in the channel was pumped out, which  
563 stretched the PDMS membrane. Otherwise, the gas channel was connected to the atmosphere,  
564 and the membrane deformation recovered. The on/off frequency of the solenoid valve was  
565 controlled by a microcontroller unit (MCU). Thus, the stretching frequency could be controlled by  
566 changing the preset program of the MCU, and the stretching amplitude could be controlled by  
567 adjusting the vacuum regulator manually. We used two pressure ranges, 10 kPa (7.18 ± 0.44%,  
568 low strain) and 15 kPa (17.28 ± 0.91%, high strain), throughout the experiments. As the control,  
569 cells were cultured in aorta-on-a-chip models under static conditions. After 24 hrs of rhythmic  
570 strain, samples were collected for immunofluorescence, RT-qPCR, western blotting and  
571 mitochondrial membrane dynamics analyses.

### 572 **Human aortic sample collection**

573 Written informed consent was obtained from all patients before participation. Human aortic  
574 specimens were utilized under approvals of Zhongshan Hospital, Fudan University Ethics  
575 Committee (NO. B2020-158) in accordance with the Declaration of Helsinki. Human aortic  
576 samples were collected from patients who underwent ascending aorta surgery at Zhongshan  
577 Hospital, Fudan University. Echocardiography was used to characterize aortic valve morphology  
578 and ascending aortic diameter prior to surgery. The tissue samples were immediately frozen in  
579 liquid nitrogen and stored at -80°C. Six aortic tissues were obtained from patients with a tricuspid  
580 aortic valve but without aortic dilation (non-diseased; mean age: 37.7 years; range: 22-47 years;  
581 4 males), and another six samples were obtained from patients with BAV-related thoracic aortic



582 aneurysm (BAV-TAA; mean age: 59.3 years; range: 43-72 years; 4 males). The patients' basic  
583 information is available in **Supplementary File-Table I**.

#### 584 **Primary human smooth muscle cell isolation**

585 Primary human aortic smooth muscle cells (p-HAoSMCs) were isolated from non-diseased aortic  
586 tissues and BAV-TAA aortic tissues (n = 3). The aortic tissues were washed with phosphate-  
587 buffered saline (PBS, Thermo Fisher Scientific). The intima and adventitia layers of the tissues  
588 were removed, and the media layer was preserved for the harvesting of p-HASMCs.  
589 Subsequently, the media layer was cut into small pieces (2-3 mm in length) and cultured in high-  
590 glucose Dulbecco's modified Eagle's medium (DMEM, Gibco) with 20% fetal bovine serum (FBS,  
591 Gibco) and 1% penicillin and streptomycin (p/s, Gibco) for 2-3 weeks at 37°C and 5% CO<sub>2</sub> in a  
592 humidified incubator. After approximately 10-12 days, the p-HASMCs started to migrate out of the  
593 tissue pieces. When the cells reached approximately 80% confluency, first-passaged cells were  
594 rinsed with PBS, digested using 0.25% trypsin (Gibco), and replated in smooth muscle cell culture  
595 medium (SMCM, ScienCell). The cells were characterized through an immunofluorescence  
596 analysis of four different specific markers of smooth muscle cells (CNN1, SM22, MYH11 and  $\alpha$ -  
597 SMA). We used p-HASMCs at a low passage (P2-P5) in all the experiments.

#### 598 **Cell culture**

599 In addition to the p-HAoSMCs isolated from aortic tissues, a human aortic smooth muscle cell line  
600 (CRL1999) and commercialized p-HAoSMCs (PCS-100-012) were purchased from ATCC in  
601 accordance with their ethical regulations and compliances. p-HAoSMCs and the CRL1999 cell  
602 line were cultured in SMCM. Prior to cell seeding, the surface of the cell culture channel was  
603 coated with mouse collagen at a concentration of 80  $\mu$ g/mL (Sigma) by incubating for 1 hr at  
604 room temperature and drying for 2 hrs at 70°C. Afterward, the cell culture channel was washed  
605 with PBS, and cells were seeded on the PDMS membranes in a cell culture channel at a density  
606 of  $2 \times 10^6$  cells/mL. The cells were cultured in Dulbecco's modified Eagle's medium/nutrient  
607 mixture F-12 (DMEM/F-12, Thermo Fisher Scientific) supplemented with 10% FBS in a cell  
608 culture channel. After seeding, aorta-on-a-chip models were incubated at 37°C and 5% CO<sub>2</sub> in a  
609 humidified incubator for 24 hrs for cell attachment. The aorta-on-a-chip models were then ready  
610 for mechanical stimulation experiments.

#### 611 **Drug screening**

612 Mdivi-1 (Sigma), an inhibitor of mitochondrial fission, was dissolved in dimethylsulfoxide (DMSO)  
613 and stored at -20°C before use, and fresh medium was used to obtain a final concentration of 30  
614  $\mu$ M. Leflunomide and teriflunomide (Sigma), two different activators of mitochondrial fusion, were  
615 dissolved in DMSO at appropriate concentrations. Prior to cell treatment, fresh medium was used  
616 to obtain a concentration of 75  $\mu$ M for both drugs. After the cells were fully attached to the PDMS  
617 membrane in the cell culture channel, medium containing a mitochondrial fusion activator  
618 (leflunomide and teriflunomide) or mitochondrial fission inhibitor (Mdivi-1) was added to the aorta-  
619 on-a-chip models. After 24 hrs of rhythmic strain, the samples were collected for comparative  
620 experiments.

#### 621 **Immunofluorescence analysis**

622 Immunofluorescence analysis was performed in the microfluidic aorta-on-a-chip model *in situ*  
623 after 24 hrs of rhythmic stretch. The medium was aspirated from the cell culture channel, and the  
624 cells were washed with PBS, immediately fixed with 4% paraformaldehyde (Beyotime) for 30 min  
625 at room temperature and permeabilized with 1% (v/v) Triton X-100 (Beyotime) for 15 min.  
626 Afterward, blocking solution with 5% bovine serum albumin (Sigma) was applied to the cells to  
627 block nonspecific binding sites for 30 min at room temperature, and the cells were incubated  
628 overnight at 4°C with primary antibodies. The primary antibodies used in this study and their  
629 working concentrations are listed in **Supplementary File-Table VI**. After incubation, the cells  
630 were washed three times with PBS and incubated with Alexa 594 anti-rabbit secondary antibody  
631 (Thermo Fisher Scientific) at a dilution of 1:300 for 1 hr at room temperature under dark

632 conditions. The nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI) (Thermo  
633 Fisher Scientific) for 10 min. The aorta-on-a-chip models were then disassembled, and images  
634 were acquired with a fluorescence microscope (Leica DMI8) and analyzed using ImageJ software.

### 635 **Western blotting**

636 Cells and aortic tissue samples were lysed using RIPA (Beyotime) lysis buffer supplemented with  
637 protease inhibitor phenyl methyl sulfonyl fluoride (PMSF, Beyotime). To collect an appropriate  
638 concentration of protein for western blotting, we collected and pooled cell protein from three  
639 microfluidic aorta-on-a-chip model. For the tissue samples, the intima and adventitia were peeled  
640 out, and the middle layers were ground into small pieces. The extracts were incubated for 30 min  
641 on ice for complete lysis and centrifuged at 14,000 rpm and 4°C for 25 min. The supernatant was  
642 collected after centrifugation, and the debris was discarded. The protein concentrations were  
643 quantified using a BCA Protein Assay kit (Thermo Fisher Scientific). The extracted proteins were  
644 diluted in sample loading buffer and heated for 5 min at 95°C. Ten micrograms of each protein  
645 sample was then separated by running on a 10% SDS-PAGE gel and subsequently transferred to  
646 0.2- $\mu$ m polyvinylidene fluoride (PVDF) membranes (Millipore). The PVDF membranes were  
647 blocked with 5% skimmed milk (Beyotime) for 1 hr at room temperature and incubated with  
648 different primary antibodies (**Supplementary File-Table VI**) overnight at 4°C. The membranes  
649 were then incubated with horseradish peroxidase-conjugated goat anti-rabbit and goat anti-  
650 mouse IgG secondary antibodies (Cell Signaling Technology) at 1:6000 dilution for 1 hr at room  
651 temperature. Bands were detected using the SuperSignal chemiluminescence reagent substrate  
652 (Millipore). The protein expression level was normalized using the housekeeping protein  $\beta$ -actin.  
653 Quantitative estimation of the band intensity was performed using Image J software.

### 654 **Knockdown of NOTCH1 by lentivirus short hairpin RNA**

655 NOTCH 1-targeted short hairpin RNA (shRNA) was designed and synthesized by GeneChem. p-  
656 HASMCs and CRL-1999 cells were seeded in six-well plates ( $6 \times 10^5$  cells/well) and cultured in a  
657 humidified incubator at 37°C with 5% CO<sub>2</sub>. When the cells reached 30% confluency, the cells  
658 were divided into three groups: control (WT), negative control shRNA (NC) and NOTCH1  
659 knockdown (NOTCH1-KD). The cells in the NC and NOTCH1-KD groups were infected with  
660 lentivirus-nonspecific shRNA and lentivirus-shRNA-NOTCH1 at a multiplicity of infection (MOI) of  
661 10 according to the manufacturer's recommended protocol (GeneChem). After 8-12 hrs of  
662 infection, the virus particles were removed from the respective wells, and fresh SMCM was added.  
663 The cells were further cultured for 72 hrs in a humidified incubator at 37°C with 5% CO<sub>2</sub>. To  
664 establish a stable cell line, the cells were treated with puromycin at a concentration of 2  $\mu$ g/mL for  
665 5 days. When the cells reached approximately 80% confluency, the cells were harvested, and the  
666 knockdown efficiency of NOTCH1 was evaluated by qRT-PCR and western blotting assays.

### 667 **Morphology and membrane potential analyses of mitochondria**

668 For analyses of the mitochondrial morphology and membrane potential, we used different types  
669 of fluorescent dyes, including tetramethylrhodamine methyl ester (TMRM), MitoSOX, and  
670 MitoTracker (all from Thermo Fisher Scientific), according to the manufacturer's guidelines. Cells  
671 were stretched on aorta-on-a-chip models for 24 hrs. An appropriate concentration of each  
672 fluorescent dye was added to three different aorta-on-a-chip models and incubated at 37°C for 30  
673 min in the dark. After incubation, the channels were washed three times with PBS, and the nuclei  
674 were counterstained with Hoechst (Sigma) for 10 min. Representative staining images of all three  
675 fluorescent dyes (under static and strain conditions) were acquired using a fluorescence  
676 microscope (Leica) and analyzed using Image J software.

### 677 **Estimation of the ATP concentration**

678 The level of ATP production by cells on the aorta-on-a-chip models was determined using an ATP  
679 assay kit (Beyotime) following the manufacturer's instructions. In brief, after mechanical  
680 stimulation of the cells on the aorta-on-a-chip models, the cells were lysed using ATP lysis buffer,  
681 and total protein was collected by centrifugation of the cell lysate at 12000 rpm and 4°C for 5 min.

682 After centrifugation, the supernatant was collected, mixed with ATP detection reagent and  
683 incubated for 10 min at room temperature. After incubation, the ATP concentration was measured  
684 using a luminometer. An ATP concentration standard curve was then established and used to  
685 calculate the ATP concentration of each sample.

### 686 **Mass spectrometry analysis**

687 The aortic samples were minced and lysed with RIPA on ice for 30 min. The extracts were  
688 centrifuged at 14,000 rpm and 4°C for 25 min, and the supernatant was collected after  
689 centrifugation. The protein concentrations were quantified using a BCA Protein Assay kit (Thermo  
690 Fisher Scientific). Filter-aided sample preparation (FASP) was performed for protein digestion.  
691 Before alkylation with 10 mM dithiothreitol (DTT, Sigma) and 30 mM iodoacetamide (IAA, Sigma),  
692 the proteins were loaded in 10-kDa centrifugal filter tubes (Millipore) and treated twice with 50  
693 mM  $\text{NH}_4\text{HCO}_3$  (Sigma). The extracts were digested with trypsin at a ratio of 1:50 and incubated at  
694 37°C overnight. Trifluoroacetic acid (TFA, 0.1%) was added to stop the digestion reaction. One  
695 hundred micrograms of peptides containing 0.1% TFA was loaded in high-pH reversed-phase  
696 fractionation spin columns (Thermo Fisher Scientific). We obtained 10 flow-through fractions, and  
697 two fractions were combined to obtain one sample. The resulting five fractions were dried by  
698 vacuum centrifugation. The samples were resuspended in 30  $\mu\text{L}$  of solvent A (A: water with 0.1%  
699 formic acid; B: ACN with 0.1% formic acid), separated by nanoLC and analyzed by on-line  
700 electrospray tandem mass spectrometry. The experiments were performed using a nanoAquity  
701 UPLC system (Waters Corporation) connected to a quadrupole-Orbitrap mass spectrometer (Q  
702 Exactive HF) (Thermo Fisher Scientific) equipped with an online nanoelectrospray ion source.  
703 Two microliters of peptide sample was loaded onto an analytical column (Acclaim PepMap C18,  
704 75  $\mu\text{m}$  x 25 cm) and subsequently separated with a linear gradient from 5% B to 30% B over 110  
705 min. The column flow rate was maintained at 300 nL/min, and the column temperature was  
706 maintained at 45°C. An electrospray voltage of 2.2 kV versus the inlet of the mass spectrometer  
707 was used.

708 The Q Exactive HF mass spectrometer was operated in the data-dependent mode to switch  
709 automatically between MS and MS/MS acquisition. Survey full-scan MS spectra ( $m/z$  350-1500)  
710 were acquired with a mass resolution of 60 K. The automatic gain control (AGC) was set to  
711 3000000 with a maximum injection time of 50 ms. Fifteen sequential high-energy collisional  
712 dissociation (HCD) MS/MS scans with a resolution of 15.0 K were acquired with the Orbitrap. The  
713 intensity threshold was 50000, and the maximum injection time was 80 ms. The AGC target was  
714 set to 100000, and the isolation window was 1.6  $m/z$ . Ions with charge states of 2+, 3+ and 4+  
715 were fragmented with a normalized collision energy (NCE) of 30%. In all cases, one microscan  
716 was recorded using dynamic exclusion of 20 s. In the MS/MS, the fixed first mass was set to 110.  
717 Online peaks were used for the analysis of proteomic data. The precursor mass error tolerance  
718 was set to 10 ppm with a fragment mass error tolerance of 0.05 Da. In all software programs,  
719 carbamidomethylation was set as a fixed modification, and variable modifications of oxidation (M),  
720 acetylation (N-term) and deamidation (NQ) were included. The false discovery rate (FDR) for  
721 peptide and protein identifications was set to 1%. Total ion chromatography (TIC) was used for  
722 normalization. The rest of the parameters were set to the default values. The MS/MS spectra  
723 were searched using the Andromeda search engine against the Swiss-Prot database (Taxonomy:  
724 Homo sapiens, Release 2020-11-02) (total of 20385 entries). The statistical analyses were mainly  
725 conducted in R 3.6.1. Label-free quantification (LFQ) was used for the following analysis flow.  
726 Proteins containing more than 50% missing values were removed, and the remaining missing  
727 values were inputted by k-nearest neighbor (kNN) imputation based on the Euclidean distance  
728 using the DMwR package in R. After normalizing the trimmed mean of M-values (TMM), PCA  
729 showed no significant batch effect. Differential expression analysis was conducted using the  
730 Limma package. The proteins with a p-value threshold of 0.05 and fold change > 1.5 were  
731 identified as differentially expressed proteins and inputted into the IPA. The mass spectrometry  
732 proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE  
733 partner repository with the dataset identifier PXD026303.

## 734 **Statistical analyses**

735 The experimental results are expressed as the means  $\pm$  standard deviations (SDs). A minimum of  
736 three individual replications of each group were used for the relative analyses. The statistical  
737 analyses were performed using GraphPad Prism 8 software. Two-tailed Student's t tests were  
738 used to compare values between two groups, and one-way or two-way analysis of variance  
739 (ANOVA) followed by Tukey's post hoc test was used for multiple-group comparisons. Statistical  
740 significance was indicated by  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$  and  $****P < 0.0001$ .

## 741 **Acknowledgments**

742 We Thank Drs. Fei Lan, Faxing Yu, Dan Ye, and Jiandong Ding at Fudan University for the  
743 helpful scientific discussions.

## 744 **Author Contributions**

745 Mieradilijiang Abudupataer, Conceptualization, Formal analysis, Investigation, Visualization,  
746 Methodology, Resources, Data curation, Validation, Methodology, Writing -original draft, Writing -  
747 review and editing; Shichao Zhu, Formal analysis, Validation, Investigation, Methodology;  
748 Shiqiang Yan, Software, Formal analysis, Methodology, Visualization; Kehua Xu, Software,  
749 Formal analysis, Methodology; Jingjing Zhang, Formal analysis, Validation, Investigation;  
750 Shaman Luo, Investigation, Methodology; Wenrui Ma, Resources, Formal analysis, Investigation;  
751 Md. Fazle Alam, Writing - review and editing; Yuyi Tang, Investigation, Methodology; Hui Huang,  
752 Investigation, Formal analysis; Nan Chen, Resources; Li Wang, Validation, Writing - review and  
753 editing; Guoquan Yan, Formal analysis, Software; Jun Li, Resources; Hao Lai, Resources;  
754 Chunsheng Wang, Conceptualization, Supervision, Writing - review and editing, Resources; Kai  
755 Zhu, Conceptualization, Visualization, Supervision, Funding acquisition, Project administration,  
756 Writing - review and editing; Weijia Zhang, Conceptualization, Visualization, Supervision, Funding  
757 acquisition, Writing - original draft, Project administration, Writing - review and editing.

## 758 **Competing Interest Statement**

759 The authors declare no competing interest.

## 760 **Funding**

761 This work was supported by grants from the National Key R&D Program of China  
762 (2018YFC1005002), the National Natural Science Foundation of China (82070482, 81771971,  
763 81772007, 21734003, and 51927805), the Shanghai Municipal Science and Technology Major  
764 Project (Grant No. 2017SHZDZX01), the Science and Technology Commission of Shanghai  
765 Municipality (17JC1400200, 20ZR1411700), and the Shanghai Municipal Education Commission  
766 (Innovation Program 2017-01-07-00-07-E00027).

## 767 **Availability of data and materials**

768 All the data associated with this study are included in the paper or Supplementary Files. The  
769 mass spectrometry proteomics data, including raw data from the mass spectrometry runs, have  
770 been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the  
771 dataset identifier PXD026303. The analyzed data are reported in Figure1 and Figure 1—source  
772 data 2-4.

## 773 **Ethics**

774 Human aortic samples were collected from patients who underwent ascending aorta surgery at  
775 Zhongshan Hospital, Fudan University. Written informed consent was obtained from all patients  
776 before participation. Human aortic specimens were utilized under approvals of Zhongshan  
777 Hospital, Fudan University Ethics Committee (NO. B2020-158).

## 778 **Supplementary File**

779 The Supplementary File include the following:  
780 Uncropped images of western blotting.  
781 Online Tables I-VI

## 782 References

- 783 **Akazawa Y**, Motoki N, Tada A, Yamazaki S, Hachiya A, Matsuzaki S, Kamiya M, Nakamura T,  
784 Kosho T, and Inaba Y. 2016. Decreased aortic elasticity in children with Marfan syndrome or  
785 Loeys-Dietz syndrome. *Circulation Journal* **80**: 2369-2375. DOI: 10.1253/circj.CJ-16-0739, PMID:  
786 27733734
- 787 **Balistreri CR**, Crapanzano F, Schirone L, Allegra A, Pisano C, Ruvolo G, Forte M, Greco E,  
788 Cavarretta E, Marullo AGM, *et al.* 2018. Deregulation of Notch1 pathway and circulating  
789 endothelial progenitor cell (EPC) number in patients with bicuspid aortic valve with and without  
790 ascending aorta aneurysm. *Scientific Reports* **8**: 13834. DOI: 10.1038/s41598-018-32170-2,  
791 PMID: 30218064
- 792 **Bell V**, Mitchell WA, Sigurðsson S, Westenberg JJM, Gotal JD, Torjesen AA, Aspelund T, Launer  
793 LJ, de Roos A, Gudnason V, *et al.* 2014. Longitudinal and circumferential strain of the proximal  
794 aorta. *Journal of the American Heart Association* **3**: e001536. DOI: 10.1161/JAHA.114.001536,  
795 PMID: 25523153
- 796 **Chen K-H**, Guo X, Ma D, Guo Y, Li Q, Yang D, Li P, Qiu X, Wen S, Xiao R-P, *et al.* 2004.  
797 Dysregulation of HSG triggers vascular proliferative disorders. *Nature Cell Biology* **6**: 872-883.  
798 DOI: 10.1038/ncb1161, PMID: 15322553
- 799 **Chen L**, Zhang J, Lyu Z, Chen Y, Ji X, Cao H, Jin M, Zhu J, Yang J, Ling R, *et al.* 2018. Positive  
800 feedback loop between mitochondrial fission and Notch signaling promotes survivin-mediated  
801 survival of TNBC cells. *Cell death & disease* **9**: 1050. DOI: 10.1038/s41419-018-1083-y, PMID:  
802 30323195
- 803 **Coady MA**, Ikonomidis JS, Cheung AT, Matsumoto AH, Dake MD, Chaikof EL, Cambria RP,  
804 Mora-Mangano CT, Sundt TM, and Sellke FW. 2010. Surgical management of descending  
805 thoracic aortic disease: open and endovascular approaches. *Circulation* **121**: 2780-2804. DOI:  
806 10.1161/CIR.0b013e3181e4d033, PMID: 20530003
- 807 **Cooper HA**, Cicalese S, Preston KJ, Kawai T, Okuno K, Choi ET, Kasahara S, Uchida HA, Otaka  
808 N, Scalia R, *et al.* 2020. Targeting mitochondrial fission as a potential therapeutic for abdominal  
809 aortic aneurysm. *Cardiovascular research* **117**: 971-982. DOI: 10.1093/cvr/cvaa133, PMID:  
810 32384150
- 811 **Eckhouse SR**, Logdon CB, Oelsen JM, Patel RK, Rice AD, Stroud RE, Wince WB, Mukherjee R,  
812 Spinale FG, Ikonomidis JS, *et al.* 2013. Reproducible porcine model of thoracic aortic aneurysm.  
813 *Circulation* **128**: S186-93. DOI: 10.1161/CIRCULATIONAHA.112.000363, PMID: 24030405
- 814 **Garg V**, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, and  
815 Srivastava D. 2005. Mutations in NOTCH1 cause aortic valve disease. *Nature* **437**: 270-274. DOI:  
816 10.1038/nature03940, PMID: 16025100
- 817 **Goldfinger JZ**, Halperin JL, Marin ML, Stewart AS, Eagle KA, and Fuster V. 2014. Thoracic  
818 aortic aneurysm and dissection. *Journal of the American College of Cardiology* **64**: 1725-1739.  
819 DOI: 10.1016/j.jacc.2014.08.025, PMID: 25323262
- 820 **Harrison OJ**, Torrens C, Salhiyyah K, Modi A, Moorjani N, Townsend PA, Ohri SK, and  
821 Cagampang F. 2019. Defective NOTCH signalling drives smooth muscle cell death and  
822 differentiation in bicuspid aortic valve aortopathy. *European Journal of Cardio-Thoracic Surgery*  
823 **56**: 117-125. DOI: 10.1093/ejcts/ezy464, PMID: 30689881
- 824 **Herrington DM**, Mao C, Parker SJ, Fu Z, Yu G, Chen L, Venkatraman V, Fu Y, Wang Y, Howard  
825 TD, *et al.* 2018. Proteomic architecture of human coronary and aortic atherosclerosis. *Circulation*  
826 **137**: 2741-2756. DOI: 10.1161/CIRCULATIONAHA.118.034365, PMID: 29915101
- 827 **High FA**, Zhang M, Proweller A, Tu L, Parmacek MS, Pear WS, and Epstein JA. 2007. An  
828 essential role for Notch in neural crest during cardiovascular development and smooth muscle  
829 differentiation. *The Journal of Clinical Investigation* **117**: 353-363. DOI: 10.1172/JCI30070, PMID:  
830 17273555
- 831 **Hofemeier AD**, Limon T, Muenker TM, Wallmeyer B, Jurado A, Afshar ME, Ebrahimi M,  
832 Tsukanov R, Oleksiievets N, Enderlein J, Gilbert PM, Betz T. 2021. Global and local tension

833 measurements in biomimetic skeletal muscle tissues reveals early mechanical homeostasis. *Elife*  
834 **10**:e60145. DOI: 10.7554/eLife.60145, PMID: 33459593

835 **Ikonomidis JS**, Gibson WC, Gardner J, Sweterlitsch S, Thompson RP, Mukherjee R, and  
836 Spinale FG. 2003. A murine model of thoracic aortic aneurysms. *Journal of Surgical Research*  
837 **115**: 157-163. DOI: 10.1016/s0022-4804(03)00193-8, PMID: 14572787

838 **Ingber DE**. 2016. Reverse engineering human pathophysiology with organs-on-chips. *Cell* **164**:  
839 1105-1109. DOI: 10.1016/j.cell.2016.02.049, PMID: 26967278

840 **Isselbacher EM**, Lino Cardenas CL, and Lindsay ME. 2016. Hereditary influence in thoracic  
841 aortic aneurysm and dissection. *Circulation* **133**: 2516-2528. DOI:  
842 10.1161/CIRCULATIONAHA.116.009762, PMID: 27297344

843 **Kasahara A**, Cipolat S, Chen Y, Dorn GW, and Scorrano L. 2013. Mitochondrial fusion directs  
844 cardiomyocyte differentiation via calcineurin and notch signaling. *Science* **342**: 734-737. DOI:  
845 10.1126/science.1241359, PMID: 24091702

846 **Koenig SN**, LaHaye S, Feller JD, Rowland P, Hor KN, Trask AJ, Janssen PM, Radtke F, Lilly B,  
847 Garg V. 2017. Notch1 haploinsufficiency causes ascending aortic aneurysms in mice. *JCI Insight*  
848 **2**:e91353. DOI: 10.1172/jci.insight.91353, PMCID: PMC5752295

849 **Li Y**, Ren P, Dawson A, Vasquez HG, Ageedi W, Zhang C, Luo W, Chen R, Li Y, Kim S, *et al.*  
850 2020. Single-cell transcriptome analysis reveals dynamic cell populations and differential gene  
851 expression patterns in control and aneurysmal human aortic tissue. *Circulation* **142**: 1374-1388.  
852 DOI: 10.1161/CIRCULATIONAHA.120.046528, PMID: 33017217

853 **Lindeman JH**, and Matsumura JS. 2019. Pharmacologic management of aneurysms. *Circulation*  
854 *research* **124**: 631-646. DOI: 10.1161/CIRCRESAHA.118.312439, PMID: 30763216

855 **Malashicheva A**, Kostina A, Kostareva A, Irtyuga O, Gordeev M, and Uspensky V. 2020. Notch  
856 signaling in the pathogenesis of thoracic aortic aneurysms: A bridge between embryonic and  
857 adult states. *Biochimica et biophysica acta Molecular basis of disease* **1866**: 165631. DOI:  
858 10.1016/j.bbdis.2019.165631, PMID: 31816439

859 **Mao N**, Gu T, Shi E, Zhang G, Yu L, and Wang C. 2015. Phenotypic switching of vascular  
860 smooth muscle cells in animal model of rat thoracic aortic aneurysm. *Interactive Cardiovascular*  
861 *and Thoracic Surgery* **21**: 62-70. DOI: 10.1093/icvts/ivv074, PMID: 25829166

862 **Michelena HI**, Khanna AD, Mahoney D, Margaryan E, Topilsky Y, Suri RM, Eidem B, Edwards  
863 WD, Sundt TM, 3rd, and Enriquez-Sarano M. 2011. Incidence of aortic complications in patients  
864 with bicuspid aortic valves. *JAMA* **306**: 1104-1112. DOI: 10.1001/jama.2011.1286, PMID:  
865 21917581

866 **Miret-Casals L**, Sebastián D, Brea J, Rico-Leo EM, Palacín M, Fernández-Salguero PM, Loza MI,  
867 Albericio F, and Zorzano A. 2018. Identification of new activators of mitochondrial fusion reveals a  
868 link between mitochondrial morphology and pyrimidine metabolism. *Cell Chemical Biology* **25**:  
869 268-278.e264. DOI: 10.1016/j.chembiol.2017.12.001, PMID: 29290623

870 **Morrison TM**, Choi G, Zarins CK, and Taylor CA. 2009. Circumferential and longitudinal cyclic  
871 strain of the human thoracic aorta: age-related changes. *Journal of Vascular Surgery* **49**: 1029-  
872 1036. DOI: 10.1016/j.jvs.2008.11.056, PMID: 19341890

873 **Nosedá M**, Fu Y, Niessen K, Wong F, Chang L, McLean G, and Karsan A. 2006. Smooth muscle  
874 alpha-actin is a direct target of Notch/CSL. *Circulation research* **98**: 1468-1470. DOI:  
875 10.1161/01.RES.0000229683.81357.26, PMID: 16741155

876 **Oller J**, Gabandé-Rodríguez E, Ruiz-Rodríguez MJ, Desdín-Micó G, Aranda JF, Rodrigues-Diez  
877 R, Ballesteros-Martínez C, Blanco EM, Roldan-Montero R, Acuña P, Forteza Gil A, Martín-López  
878 CE, *et al.* 2021. Extracellular tuning of mitochondrial respiration leads to aortic aneurysm.  
879 *Circulation*. DOI: 10.1161/CIRCULATIONAHA.120.051171, PMID: 33709773.

880 **Olsson C**, Thelin S, Ståhle E, Ekbom A, and Granath F. 2006. Thoracic aortic aneurysm and  
881 dissection: increasing prevalence and improved outcomes reported in a nationwide population-  
882 based study of more than 14,000 cases from 1987 to 2002. *Circulation* **114**: 2611-2618. DOI:  
883 10.1161/CIRCULATIONAHA.106.630400, PMID: 17145990

884 **Park SE**, Georgescu A, and Huh D. 2019. Organoids-on-a-chip. *Science* **364**: 960-965. DOI:  
885 10.1126/science.aaw7894, PMID: 31171693

886 **Petsophonsakul P**, Furmanik M, Forsythe R, Dweck M, Schurink GW, Natour E,  
887 Reutelingsperger C, Jacobs M, Mees B, and Schurgers L. 2019. Role of vascular smooth muscle  
888 cell phenotypic switching and calcification in aortic aneurysm formation. *Arteriosclerosis,*  
889 *Thrombosis, and Vascular Biology* **39**: 1351-1368. DOI: 10.1161/ATVBAHA.119.312787, PMID:  
890 31144989

891 **Prakash SK**, Bossé Y, Muehlschlegel JD, Michelena HI, Limongelli G, Della Corte A, Pluchinotta  
892 FR, Russo MG, Evangelista A, Benson DW, *et al.* 2014. A roadmap to investigate the genetic  
893 basis of bicuspid aortic valve and its complications: insights from the International BAVCon  
894 (Bicuspid Aortic Valve Consortium). *Journal of the American College of Cardiology* **64**: 832-839.  
895 DOI: 10.1016/j.jacc.2014.04.073, PMID: 25145529

896 **Salabei JK**, and Hill BG. 2013. Mitochondrial fission induced by platelet-derived growth factor  
897 regulates vascular smooth muscle cell bioenergetics and cell proliferation. *Redox Biology* **1**: 542-  
898 551. DOI: 10.1016/j.redox.2013.10.011, PMID: 24273737

899 **Sciacca S**, Pilato M, Mazzoccoli G, Paziienza V, and Vinciguerra M. 2013. Anti-correlation  
900 between longevity gene SirT1 and Notch signaling in ascending aorta biopsies from patients with  
901 bicuspid aortic valve disease. *Heart and Vessels* **28**: 268-275. DOI: 10.1007/s00380-012-0238-5,  
902 PMID: 22370592

903 **Shao S**, Zhao X, Zhang X, Luo M, Zuo X, Huang S, Wang Y, Gu S, and Zhao X. 2015. Notch1  
904 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-  
905 dependent manner. *Molecular cancer* **14**: 28. DOI: 10.1186/s12943-015-0295-3, PMID: 25645291

906 **Thacker VV**, Dhar N, Sharma K, Barrile R, Karalis K, McKinney JD. 2020. A lung-on-chip model  
907 of early Mycobacterium tuberculosis infection reveals an essential role for alveolar epithelial cells  
908 in controlling bacterial growth. *Elife* **9**:e59961. DOI: 10.7554/eLife.59961, PMID: 33228849

909 **van der Pluijm I**, Burger J, van Heijningen PM, A IJ, van Vliet N, Milanese C, Schoonderwoerd K,  
910 Sluiter W, Ringuette LJ, Dekkers DHW, *et al.* 2018. Decreased mitochondrial respiration in  
911 aneurysmal aortas of Fibulin-4 mutant mice is linked to PGC1A regulation. *Cardiovascular*  
912 *research* **114**: 1776-1793. DOI: 10.1093/cvr/cvy150, PMID: 29931197

913 **Vasquez-Trincado C**, Garcia-Carvajal I, Pennanen C, Parra V, Hill JA, Rothermel BA, and  
914 Lavandero S. 2016. Mitochondrial dynamics, mitophagy and cardiovascular disease. *The Journal*  
915 *of physiology* **594**: 509-525. DOI: 10.1113/JP271301, PMID: 26537557

916 **Verma S**, and Siu SC. 2014. Aortic dilatation in patients with bicuspid aortic valve. *New England*  
917 *Journal of Medicine* **370**: 1920-1929. DOI: 10.1056/NEJMra1207059, PMID: 24827036

918 Zhang B, Korolj A, Lai BF, Radisic M. 2018. Advances in organ-on-a-chip engineering. *Nature*  
919 *Reviews Materials* **3**:257–278. DOI: 10.1038/ s41578-018-0034-7.

920 **Zhao Y**, Rafatian N, Feric NT, Cox BJ, Aschar-Sobbi R, Wang EY, Aggarwal P, Zhang B, Conant  
921 G, Ronaldson-Bouchard K, Pahnke A, *et al.* 2019. A platform for generation of chamber-specific  
922 cardiac tissues and disease modeling. *Cell* **176**:913-927.e18. DOI: 10.1016/j.cell.2018.11.042,  
923 PMID: 30686581

924

## Figures and figure supplements


medRxiv preprint doi: <https://doi.org/10.1101/2021.07.07.21260132>; this version posted July 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

### **Aorta-on-a-chip reveals impaired hemochromatosis dynamics as a therapeutic target for aortic aneurysm in bicuspid aortic valve disease**


Mieradilijiang Abudupataer<sup>1</sup>, Shichao Zhu<sup>1</sup>, Shiqiang Yan<sup>2</sup>, Kehua Xu<sup>2</sup>, Jingjing Zhang<sup>2</sup>, Shaman Luo<sup>2,3</sup>, Wenrui Ma<sup>1</sup>, Md. Fazle Alam<sup>2,3</sup>, Yuyi Tang<sup>2</sup>, Hui Huang<sup>2</sup>, Nan Chen<sup>1</sup>, Li Wang<sup>2</sup>, Guoquan Yan<sup>2</sup>, Jun Li<sup>1</sup>, Hao Lai<sup>1</sup>, Chunsheng Wang<sup>1\*</sup>, Kai Zhu<sup>1\*</sup>, Weijia Zhang<sup>1,2,3\*</sup>

<sup>1</sup> Department of Cardiac Surgery and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China; <sup>2</sup> Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China; <sup>3</sup> The State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 200438, China.







**Figure 1. The relationship between NOTCH1 insufficiency and mitochondrial dysfunction in BAV-TAA.** (a) H&E staining of non-diseased and BAV-TAA aortic tissues. The scale bar represents 1 mm in the low field and 200  $\mu\text{m}$  in the high field. (b) Representative images of the western blotting analysis of the expression of NOTCH1, the mitochondrial dynamics proteins DRP-1, MFF, MFN1, and MFN2 and the contractile phenotype proteins SM22 and CNN1 in six non-diseased and six BAV-TAA aortic tissue fragments. (c) Quantification of the total band densities of the proteins normalized to the corresponding band density of  $\beta$ -actin ( $n = 6$ ,  $*P < 0.05$ , two-tailed Student's t tests were used between two groups). (d) Correlation analysis among the quantified protein expression levels of NOTCH1, MFN1 and MFN2. A positive correlation was found between NOTCH1 and MFN1 or MFN2 in aortic tissues. The  $R^2$  between NOTCH1 and MFN2 was 0.8069, and that between NOTCH1 and MFN1 was 0.6137. (e) Correlation analysis between the quantified protein expression of NOTCH1 and DRP1 or MFF. No correlation was found. (f) The enriched canonical pathways were identified by IPA. Mass spectrometry-based comparative proteomics showed that mitochondrial dysfunction and the oxidative phosphorylation pathways were significantly enriched in BAV-TAA aortic tissues. (g) Heatmap of the expression of enriched proteins involved in mitochondrial dysfunction, the oxidative phosphorylation pathways and acute phase response signaling. (h) Volcano plot visualization of the differentially expressed proteins related to mitochondrial dysfunction. The colors indicate the following: gray, no differential expression; red, upregulated proteins; and blue, downregulated proteins. The proteins related to mitochondrial dysfunction are labeled. All the data are expressed as the means  $\pm$  SDs.



**Figure 2. Schematic design and strain characterization of the aorta-on-a-chip model.** (a) Schematic overview of the in vitro chip model. (b) Cross-sectional view of the microfluidic aorta-on-a-chip model showing the deformations of the PDMS membranes under different vacuum pressures. The scale bar represents 5 mm. (c) Measured tensile strains of the upper (red) and lower (blue) membranes at negative pressures of 10 kPa and 15 kPa for five cycles. The peak tensile strain per cycle averaged  $7.18 \pm 0.44\%$  with a cyclic negative pressure of 10 kPa and  $17.28 \pm 0.91\%$  with a cyclic negative pressure of 15 kPa.




**Figure 3. Effect of rhythmic strain on the cell morphology, alignment and phenotype.** (a) Schematic workflow of cell culture on the chip model. (b) Representative images of cytoskeletal F-actin staining of HAoSMCs exposed to low or high rhythmic strain for 24 hrs. The scale bar represents 200  $\mu\text{m}$ . (c) Length-to-width ratio of HAoSMCs after exposure to low or high rhythmic strain for 24 hrs. ( $n = 3$ , cells were measured in three fields per sample, \*\*\*\* $P < 0.0001$ , one-way ANOVA followed by Tukey's post hoc test). (d) Alignments of HAoSMCs exposed to low or high rhythmic strain for 24 hrs. (e) Representative images of the western blotting analyses of protein markers of the contractile phenotype (SM22 and CNN1) and synthetic phenotype (OPN) of HAoSMCs after exposure to low or high rhythmic strain for 24 hrs. (f) Quantification of the total band densities for individual proteins normalized to the corresponding band of  $\beta$ -actin ( $n = 4$ , \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ , one-way ANOVA followed by Tukey's post hoc test). All the data are expressed as the means  $\pm$  SDs.




**Figure 4. Phenotypic switching of NOTCH1-insufficient HAoSMCs under static and rhythmic strain conditions.** (a) Schematic workflow of NOTCH1-KD HAoSMCs on the chip model. (b)

Representative images of immunofluorescence staining of SM22 and CNN1 after exposure to rhythmic low or high strain for 24 hrs. The scale bar represents 200  $\mu$ m. (c) Intensity of immunofluorescence staining of SM22 and CNN1 (\* $P$  < 0.05, \*\* $P$  < 0.01, \*\*\*\* $P$  < 0.0001, two-way ANOVA followed by Tukey's post hoc test). (d) Representative images of the western blotting analyses of SM22 and CNN1 in the WT and NOTCH1-KD groups exposed to rhythmic low or high strains for 24 hrs. (e) Quantification of the total band densities for individual proteins normalized to the corresponding band density of  $\beta$ -actin ( $n$  = 4, \*\* $P$  < 0.01, \*\*\* $P$  < 0.001, \*\*\*\* $P$  < 0.0001, two-way ANOVA followed by Tukey's post hoc test). All the data are expressed as the means  $\pm$  SDs.



**Figure 5. Effect of NOTCH1 insufficiency on mitochondrial dynamics and function in HAoSMCs.**

(a) Representative images of the western blotting analyses of MFN1, MFN2, DRP1 and MFF expression in the WT and NOTCH1-KD groups under rhythmic low or high strain or static conditions. (b) Quantification of the total band densities for four individual proteins normalized to the corresponding band density of  $\beta$ -actin ( $n = 4$ ,  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ ,  $****P < 0.0001$ , two-way ANOVA followed by Tukey's post hoc test). (c) MitoTracker staining images of the mitochondrial morphologies in the WT and NOTCH1-KD groups under rhythmic low or high strain or static conditions. The scale bar represents  $50 \mu\text{m}$ . (d) Quantification of the mitochondria length ( $n = 3$ ,  $**P < 0.01$ ,  $****P < 0.0001$ , two-way ANOVA followed by Tukey's post hoc test). (e) TMRM staining of the mitochondrial membrane potentials in the WT and NOTCH1-KD groups under rhythmic low or high strain or static conditions. The scale bar represents  $100 \mu\text{m}$ . (f) Quantification of the relative TMRM fluorescence intensity ( $**P < 0.01$ , two-way ANOVA followed by Tukey's post hoc test). (g) MitoSOX staining of mitochondrial superoxide generation in the WT and NOTCH1-KD groups. The scale bar represents  $100 \mu\text{m}$ . (h) Quantification of the relative MitoSOX fluorescence intensity ( $*P < 0.05$ ,  $**P < 0.01$ , two-way ANOVA followed by Tukey's post hoc test). (i) The ATP concentrations were measured using an ATP Determination Kit ( $**P < 0.01$ , two-way ANOVA followed by Tukey's post hoc test). Quantitative measurements were calculated using ImageJ software. All the data are expressed as the means  $\pm$  SDs.



**Figure 6. Screening of drugs that can rescue the cell phenotype and mitochondrial dynamics using the chip model.** (a) Schematic workflow of the experimental design. After treatment with treated with Mdivi-1, leflunomide and teriflunomide on the chip models with (b) a NOTCH1-knockdown HAoSMC cell line (CRL1999), (c) NOTCH1-knockdown p-HAoSMCs isolated from non-diseased aortic tissues, (d) NOTCH1-knockdown p-HAoSMCs purchased from ATCC, and (e-g) p-HAoSMCs isolated from aortic tissues from three patients with BAV-TAA, quantification of the total band densities of the mitochondria-related proteins MFN1, MFN2, DRP-1, and MFF and the contractile phenotype proteins SM22 and CNN1 were normalized to the corresponding band densities of  $\beta$ -actin. All the data are expressed as the means  $\pm$  SDs.  $n = 3$ ,  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ ,  $****P < 0.0001$ , one-way ANOVA followed by Tukey's post hoc test.


## Figures and figure supplements

medRxiv preprint doi: <https://doi.org/10.1101/2021.07.07.21260132>; this version posted July 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

### **Aorta-on-a-chip reveals impaired hemochromatosis dynamics as a therapeutic target for aortic aneurysm in bicuspid aortic valve disease**


Mieradilijiang Abudupataer<sup>1</sup>, Shichao Zhu<sup>1</sup>, Shiqiang Yan<sup>2</sup>, Kehua Xu<sup>2</sup>, Jingjing Zhang<sup>2</sup>, Shaman Luo<sup>2,3</sup>, Wenrui Ma<sup>1</sup>, Md. Fazle Alam<sup>2,3</sup>, Yuyi Tang<sup>2</sup>, Hui Huang<sup>2</sup>, Nan Chen<sup>1</sup>, Li Wang<sup>2</sup>, Guoquan Yan<sup>2</sup>, Jun Li<sup>1</sup>, Hao Lai<sup>1</sup>, Chunsheng Wang<sup>1\*</sup>, Kai Zhu<sup>1\*</sup>, Weijia Zhang<sup>1,2,3\*</sup>

<sup>1</sup> Department of Cardiac Surgery and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China; <sup>2</sup> Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China; <sup>3</sup> The State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 200438, China.




**Figure 2—figure supplement 1. Characterization and parameters of the aorta-on-a-chip model. (a)** Assembly and parameters of the PDMS aorta-on-a-chip model. **(b)** Young's modulus of the PDMS membrane. **(c)** Membrane deformation under different vacuum pressures (0 kPa, 10 kPa, 15 kPa and 20 kPa).





**Figure 4—figure supplement 1. Alteration of NOTCH1 signaling, phenotype and mitochondrial dynamics in HAoSMCs after NOTCH1 shRNA transfection.** (a) Expression of the NOTCH1, SM22, CNN1 and OPN1 genes in the NOTCH1-KD group compared with the group without virus (WT) and the negative control (NC) group by quantitative real-time PCR under static conditions. (b) Representative images of the western blotting analysis of NOTCH1, NICD, SM22 and CNN1 in the WT, NC and NOTCH1-KD groups under static conditions. (c) Quantification of the total band densities of individual proteins normalized to the corresponding band intensity of  $\beta$ -actin. (d) Representative images of the western blotting analysis of MFN1, MFN2, DRP1 and MFF in the WT, NC and NOTCH1-KD groups under static conditions. (e) Quantification of the total band densities of individual proteins normalized to the corresponding band density of  $\beta$ -actin. All the data are expressed as the means  $\pm$  SDs.  $n = 3$ ,  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ ,  $****P < 0.0001$ , one-way ANOVA followed by Tukey's post hoc test.



**Figure 6—figure supplement 1. Expression of NOTCH1 and phenotype- and mitochondrial dynamics-related proteins in p-HAoSMCs from BAV-TAA aortic tissues.** Image of the western blotting analysis of NOTCH1, the mitochondrial dynamics proteins MFN1 and MFN2 and the contractile phenotype proteins SM22 and CNN1 in primary HAoSMCs from BAV-TAA tissue with or without rhythmic strain.